Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name belantamab mafodotin-blmf
Synonyms
Therapy Description

Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262). Blenrep (belantamab mafodotin-blmf) is FDA approved for use in patients with relapse or refractory multiple myeloma who have received 4 or more prior therapies (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
belantamab mafodotin-blmf Blenrep anti-BCMA ADC GSK2857916|J6M0-mcMMAF|GSK2857916 TNFRSF17 Antibody 18 Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262). Blenrep (belantamab mafodotin-blmf) is FDA approved for use in patients with relapse or refractory multiple myeloma who have received 4 or more prior therapies (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05091372 Phase II belantamab mafodotin-blmf Lenalidomide Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Recruiting USA 0
NCT05874193 Phase II belantamab mafodotin-blmf A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed Refractory Myeloma (COSTA) Not yet recruiting USA 0
NCT04126200 Phase II belantamab mafodotin-blmf + Isatuximab belantamab mafodotin-blmf + Dostarlimab-gxly belantamab mafodotin-blmf + GSK3359609 belantamab mafodotin-blmf + Nirogacestat belantamab mafodotin-blmf belantamab mafodotin-blmf + GSK3174998 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) Recruiting USA | NLD | FRA | ESP | DEU | CAN | AUS 10
NCT03525678 Phase II belantamab mafodotin-blmf A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 0
NCT04398680 Phase I belantamab mafodotin-blmf A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13) Recruiting USA 2
NCT04680468 Phase II belantamab mafodotin-blmf Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma Recruiting USA 0
NCT05461209 Phase III belantamab mafodotin-blmf Talquetamab-tgvs A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5) Withdrawn USA 1
NCT05055063 Phase I belantamab mafodotin-blmf A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT04398745 Phase I belantamab mafodotin-blmf A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12) Recruiting USA 3
NCT05065047 Phase I belantamab mafodotin-blmf Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma Recruiting USA 0
NCT05064358 Phase II belantamab mafodotin-blmf Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 11
NCT04676360 Phase II belantamab mafodotin-blmf Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma Recruiting USA 0
NCT04162210 Phase III Dexamethasone + Pomalidomide belantamab mafodotin-blmf Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT05847569 Phase II belantamab mafodotin-blmf Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma Recruiting USA 0
NCT05117008 Phase II belantamab mafodotin-blmf Maintenance Belantamab Mafodotin (Blenrep) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE) Recruiting USA 0
NCT05714839 Phase I Belantamab Belantamab + belantamab mafodotin-blmf + Dexamethasone + Lenalidomide belantamab mafodotin-blmf A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20) Recruiting GBR | AUS 8


Additional content available in CKB BOOST